Looks like you’re on the UK site. Choose another location to see content specific to your location

15th December 2008

Bayer has said it is to further expand its research and development activities, despite the current economic situation.

Those looking for science sales jobs may be interested to hear the company stated its pharmaceutical pipeline is "well filled", with 50 projects in phases I to III development and testing, with ten new crop protection active ingredients scheduled to come onto the market in the next four years.

Werner Wenning, chairman of the board of management at Bayer, said in an address to 130 journalists that the company’s task now is to get on the "right course".

"Only through innovation can our company generate the growth that is essential to safeguard its sustained success," he added.

Noting issues such as the expanding world population and resulting scarcity of resources, as well as climate change, Mr Wenning went on to say: "Bayer can make a contribution to meeting all of these challenges."

Last week, the company’s Xarelto treatment was found to reduce symptomatic venous thromboembolism in patients who have had knee or hip replacement surgery.

When compared to Enoxaparin, results involving more than 12,500 patients showed a 50 per cent decrease in the composite primary efficacy endpoint.
ADNFCR-1050-ID-18928836-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.